Patient Related Outcomes in Sjögren Syndrome Treated with Stimulants of Salivary Secretion: Randomized Clinical Trial.
To investigate the impact of Gustatory Stimulants of Salivary Secretion (GSSS) on Sjögren's syndrome patients' self-perception of xerostomia, Oral Health Related Quality of Life (OHRQoL) and salivary secretion. 110 Sjögren's syndrome patients were randomly allocated to be treated with either a malic acid lozenge or a citric acid mouthwash and then crossed over. Before and after the interventions, the Xerostomia Inventory 5 (SXI-5-PL) and the Oral Health Impact Profile (OHIP-14-PT) questionnaires (both in the Portuguese language) were administered to patients. Unstimulated, mechanical and gustatory stimulated salivary flows were determined. Repeated measures and between subject analyses were performed. Statistical significance was set at 5%. After the intervention and within each group, both GSSS elicited a reduction in the SXI-5-PL and OHIP-14-PT scores and an increase in salivary output, significant in the malic acid lozenge group. The malic acid treatment resulted in a greater effect size and percentage improvement than citric acid mouthwash. The malic acid lozenge also produced a significant greater salivary output than the citric acid rising solution. In Sjögren's syndrome patients, lozenges containing malic acid increased saliva production and xerostomia relief, resulting in improved quality of life.